JAK inhibitors show fast results, improved QOL, low adverse events in IBD

MAUI, Hawaii — JAK inhibitors offer quick results, improved quality of life and lower serious adverse events for patients with inflammatory bowel disease, according to an expert at the GUILD Conference 2020.“JAK inhibition represents a potent, fast-acting mechanism of action,” Edward V. Loftus Jr, MD, professor of medicine at the division of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minnesota, said during his presentation. “Tofacitinib [Xeljanz, Pfizer] is approved for moderate-to-severe UC in patients who have failed anti-TNFs. The selectiveRead More

Share on facebook
Share on twitter
Share on linkedin